Keyword: Hanmi Pharmaceutical
Astellas buys gene therapy player Audentes for $3 billion. Keytruda and Opdivo fail to win coverage in China. Hanmi inks I-O deal with Rapt.
Hanmi loses Janssen obesity pact, while Yuhan signs NASH deal with Boehringer. GSK sells a Chinese site to Fosun as it opens facilities in Singapore.
Eisai's stock plummets at AD failure; Keytruda has much upside in China, analysts say; Korea Exchange is dragged into Samsung accounting probe.
Spectrum Pharmaceuticals has pulled its biologics license application for Rolontis because the FDA needs more CMC information.
Shire nixed Takeda's $60 billion-plus buyout offer, Hanmi ditched lung cancer hopeful olmutinib, Grail is looking for $1 billion before Hong Kong IPO.
Takeda weighs a $52 billion Shire bid, WuXi gets approval for a $900M-plus Shanghai IPO, Aslan aims to raise $86 million through an IPO on Nasdaq.
South Korea’s Hanmi Pharmaceutical expects growth from its $140 million smart drug manufacturing facility in its move toward the CDMO market.
Novartis' CEO said China's pharma market will surpass $300 billion by 2020, Hanmi failed to report olmutinib side effect on time, Celgene tapped first Asia-Pacific partner.
Clinical trials for a new long-term diabetes treatment being developed by Sanofi have been pushed back because South Korea partner Hanmi Pharmaceutical has had a glitch in manufacturing.
South Korean authorities are investigating allegations of insider trading ahead of Boehringer Ingelheim's decision to hand back hot-potato rights to a Hanmi Pharma drug last week.